Research Article
VDAC1 Conversely Correlates with Cytc Expression and Predicts Poor Prognosis in Human Breast Cancer Patients
Table 5
Correlation between the expression of VDAC1, Cytc, and clinicopathologic parameters.
| | | VDAC1 | value | Cytc | value | | High () | Low () | High () | Low () |
| | Age | | | | 0.636 | | | 0.763 | | ≤50 | 135 | 98 (72.59%) | 37 (27.41%) | | 39 (28.89%) | 96 (71.11%) | | | >50 | 84 | 64 (76.19%) | 20 (23.81%) | | 26 (30.95%) | 58 (69.05%) | | | Menopause | | | | 0.878 | | | 0.455 | | Before | 125 | 93 (74.4%) | 32 (25.6%) | | 40 (32%) | 85 (68%) | | | After | 94 | 69 (73.4%) | 25 (26.6%) | | 25 (26.6%) | 69 (73.4%) | | | Recurrence | | | | 0.000 | | | 0.004 | | No | 136 | 85 (62.5%) | 51 (37.5%) | | 50 (36.76%) | 86 (63.24%) | | | Yes | 83 | 77 (92.77%) | 6 (7.23%) | | 15 (18.07%) | 68 (81.93%) | | | TNM stage | | | | 0.007 | | | 0.895 | | I/II | 153 | 105 (68.63%) | 48 (31.37%) | | 45 (29.41%) | 108 (70.59%) | | | III | 66 | 57 (86.36%) | 9 (13.64%) | | 20 (30.3%) | 46 (69.7%) | | | Lymph node metastasis | | | | 0.030 | | | 0.953 | | No | 95 | 63 (66.32%) | 32 (33.68%) | | 28 (29.47%) | 67 (70.53%) | | | Yes | 124 | 99 (79.84%) | 25 (20.16%) | | 37 (29.84%) | 87 (70.16%) | | | Histological grade | | | | 0.033 | | | 0.041 | | G1/G2 | 165 | 116 (70.3%) | 49 (29.7%) | | 55 (33.33%) | 110 (66.67%) | | | G3 | 54 | 46 (85.19%) | 8 (14.81%) | | 10 (18.52%) | 44 (81.48%) | | | HER2 gene | | | | 0.008 | | | 0.591 | | Nonamplification | 173 | 121 (69.94%) | 52 (30.06%) | | 53 (30.64%) | 120 (69.36%) | | | Amplification | 46 | 41 (89.13%) | 5 (10.87%) | | 12 (26.09%) | 34 (73.91%) | | | ER status | | | | 0.440 | | | 0.037 | | Negative | 122 | 93 (76.23%) | 29 (23.77%) | | 29 (23.77%) | 93 (76.23%) | | | Positive | 97 | 69 (71.13%) | 28 (28.87%) | | 36 (37.11%) | 61 (62.89%) | | | PR status | | | | 0.535 | | | 0.025 | | Negative | 124 | 94 (75.81%) | 30 (24.19%) | | 29 (23.39%) | 95 (76.61%) | | | Positive | 95 | 68 (71.58%) | 27 (28.42%) | | 36 (37.89%) | 59 (62.11%) | |
|
|
